Bristol Myers Squibb Competitors and Similar CompaniesClear all
AstraZeneca's competitors and similar companies include Eli Lilly, Johnson & Johnson, Novartis, Pfizer, Catalent, Lonza, Merck Group, Gilead Sciences, Daiichi Sankyo, Edwards Lifesciences and AbbVie.
 AstraZeneca AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines. |  Eli Lilly Eli Lilly and Company is a company that discovers, develops, manufactures, and markets pharmaceutical products. |  Johnson & Johnson Johnson & Johnson (J&J) is a company that engages in the research and development, manufacture, and sale of a range of products in the healthcare field. |  Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. |  Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products. |  Catalent Catalent is a company that develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products. |  Lonza Lonza Group is a company that supplies active ingredients, chemical intermediates, and biotechnology solutions to the pharmaceutical and agrochemical industries. |  Gilead Sciences Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines. |  Edwards Lifesciences Edwards Lifesciences is a provider of patient-focused medical solutions for structural heart disease and critical care monitoring. |  AbbVie AbbVie is a pharmaceutical company engaged in the research and development, manufacturing, commercialization, and sale medicines and therapies. | |||
Founding Date | Founding Date 1999 | Founding Date 1876 | Founding Date 1886 | Founding Date 1996 | Founding Date 1849 | Founding Date 2007 | Founding Date 1897 | Founding Date 1668 | Founding Date 1987 | Founding Date 2005 | Founding Date 1958 | Founding Date 2013 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||||||||
Locations | Locations Cambridge, GB HQ Alger, DZ Buenos Aires, AR Haedo, AR Macquarie Park, AU Macquarie Park, AU North Ryde, AU see more | Locations HQ | Locations New Brunswick, US HQ Buenos Aires, AR Sydney, AU Ultimo, AU Wien, AT Minsk, BY Beerse, BE see more | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Bentley, AU Footscray, AU Mulgrave, AU Sydney, AU see more | Locations Somerset, US HQ Buenos Aires, AR Bruxelles, BE Charleroi, BE Charleroi, BE Charleroi, BE Indaiatuba, BR see more | Locations HQ | Locations HQ | Locations Foster City, US HQ Buenos Aires, AR Melbourne, AU Wien, AT Machelen, BE São Paulo, BR Edmonton, CA see more | Locations Tokyo, JP HQ Wien, AT Braine L'alleud, BE Sao Paulo, BR São Paulo, BR Beijing, CN Shanghai, CN see more | Locations Irvine, US HQ Macquarie Park, AU Wien, AT Dilbeek, BE São Paulo, BR Mississauga, CA Shanghai, CN see more | |
Employees | Employees 83,500 | Employees 35,000 | Employees 152,700 | Employees 101,7033% decrease | Employees 83,0005% increase | Employees 19,00010% increase | Employees 17,896 | Employees 63,297 | Employees 14,4006% increase | Employees 16,4583% increase | Employees 17,30010% increase | Employees 50,000 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 564.9 b | Valuation ($) 363.1 b | Valuation ($) N/A | Valuation ($) 171.2 b | Valuation ($) 7.2 b | Valuation ($) N/A | Valuation ($) 74.4 b | Valuation ($) 97.6 b | Valuation ($) 53.4 b | Valuation ($) 41.5 b | Valuation ($) 254.5 b |
Twitter followers | Twitter followers 303.8 k | Twitter followers N/A | Twitter followers 250 k | Twitter followers 301.8 k | Twitter followers 491.8 k | Twitter followers 19 k | Twitter followers 8.1 k | Twitter followers 24.9 k | Twitter followers 73.8 k | Twitter followers 683 | Twitter followers 10.6 k | Twitter followers 78.9 k |
Number of tweets (last 30 days) | Number of tweets (last 30 days) 22 | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) 8 | Number of tweets (last 30 days) 4 | Number of tweets (last 30 days) 16 | Number of tweets (last 30 days) 116 | Number of tweets (last 30 days) 1 | Number of tweets (last 30 days) 51 | Number of tweets (last 30 days) 22 | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) 8 | Number of tweets (last 30 days) 52 |
Average likes per tweet (last 30 days) | Average likes per tweet (last 30 days) 14.1 | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) 13.9 | Average likes per tweet (last 30 days) 8.5 | Average likes per tweet (last 30 days) 63.4 | Average likes per tweet (last 30 days) 0.4 | Average likes per tweet (last 30 days) 15 | Average likes per tweet (last 30 days) 5.9 | Average likes per tweet (last 30 days) 48.1 | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) 5.4 | Average likes per tweet (last 30 days) 5.2 |
Percentage of tweets with engagement (last 30 days) | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) 75% | Percentage of tweets with engagement (last 30 days) 75% | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 33.62% | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 96.08% | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 88.46% |
Employee Rating | Employee Rating 4.2 | Employee Rating 4 | Employee Rating 4.2 | Employee Rating 4.2 | Employee Rating 4.2 | Employee Rating 3.5 | Employee Rating 3.3 | Employee Rating 4.1 | Employee Rating 3.8 | Employee Rating 3.8 | Employee Rating 4 | Employee Rating 3.9 |
Financial | ||||||||||||
Revenue (est.) | Revenue (est.) $44.4b (FY, 2022) | Revenue (est.) $28.5b (FY, 2022) | Revenue (est.) $94.9b (FY, 2022) | Revenue (est.) $51.8b (FY, 2022) | Revenue (est.) $100.3b (FY, 2022) | Revenue (est.) $4.8b (FY, 2022) | Revenue (est.) CHF6.2b (FY, 2022) | Revenue (est.) €22.2b (FY, 2022) | Revenue (est.) $27.3b (FY, 2022) | Revenue (est.) ¥1t (FY, 2021) | Revenue (est.) $5.4b (FY, 2022) | Revenue (est.) $58.1b (FY, 2022) |
Cost of goods | Cost of goods $11.3b (FY, 2022) | Cost of goods $6.6b (FY, 2022) | Cost of goods $31.1b (FY, 2022) | Cost of goods $8.3b (FY, 2022) | Cost of goods $34.3b (FY, 2022) | Cost of goods $3.2b (FY, 2022) | Cost of goods CHF3.1b (FY, 2022) | Cost of goods €7.1b (FY, 2022) | Cost of goods $5.7b (FY, 2022) | Cost of goods ¥353.3b (FY, 2021) | Cost of goods $1.1b (FY, 2022) | Cost of goods $17.4b (FY, 2022) |
Gross profit | Gross profit $33.6b (FY, 2022) | Gross profit $21.9b (FY, 2022) | Gross profit $63.9b (FY, 2022) | Gross profit $44.3b (FY, 2022) | Gross profit $66b (FY, 2022) | Gross profit $1.6b (FY, 2022) | Gross profit CHF3.3b (FY, 2022) | Gross profit €15.5b (FY, 2022) | Gross profit $21.6b (FY, 2022) | Gross profit ¥691.6b (FY, 2021) | Gross profit $4.3b (FY, 2022) | Gross profit $40.6b (FY, 2022) |
Net income | Net income $3.3b (FY, 2022) | Net income $6.2b (FY, 2022) | Net income $17.9b (FY, 2022) | Net income $7b (FY, 2022) | Net income $31.4b (FY, 2022) | Net income $499m (FY, 2022) | Net income CHF1.2b (FY, 2022) | Net income €3.3b (FY, 2022) | Net income $4.6b (FY, 2022) | Net income ¥67b (FY, 2021) | Net income $1.5b (FY, 2022) | Net income $11.8b (FY, 2022) |
Operating ⚠ | ||||||||||||
Countries | Countries 130 (FY, 2021) | Countries 120 (FY, 2021) | Countries N/A | Countries N/A | Countries 125 (FY, 2021) | Countries 85 (FY, 2020) | Countries 30 (FY, 2021) | Countries 66 (FY, 2021) | Countries 35 (FY, 2021) | Countries N/A | Countries 100 (FY, 2022) | Countries 70 (FY, 2022) |
Manufacturing Facilities | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities 13 (Jun, 2022) | Manufacturing Facilities 7 (FY, 2022) | Manufacturing Facilities 19 (FY, 2022) |
Manufacturing Facilities (United States) | Manufacturing Facilities (United States) N/A | Manufacturing Facilities (United States) N/A | Manufacturing Facilities (United States) 28 (FY, 2022) | Manufacturing Facilities (United States) N/A | Manufacturing Facilities (United States) N/A | Manufacturing Facilities (United States) N/A | Manufacturing Facilities (United States) N/A | Manufacturing Facilities (United States) N/A | Manufacturing Facilities (United States) N/A | Manufacturing Facilities (United States) N/A | Manufacturing Facilities (United States) N/A | Manufacturing Facilities (United States) 11 (FY, 2022) |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 27 (FY, 2019) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 27 (FY, 2021) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 16 (FY, 2018) | Phase I Trials Products N/A | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products 8 (FY, 2021) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 25 (FY, 2021) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 7 (FY, 2018) | Phase II Trials Products N/A | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 10 (FY, 2021) | Phase III Trials Products N/A | Phase III Trials Products 44 (FY, 2022) | Phase III Trials Products 27 (FY, 2021) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 9 (FY, 2021) | Phase III Trials Products 7 (FY, 2018) | Phase III Trials Products N/A | Phase III Trials Products N/A |
Phase III Trials Products (Oncology) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 27 (FY, 2021) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 4 (FY, 2021) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A |
Products | Products N/A | Products N/A | Products N/A | Products N/A | Products N/A | Products 7 k (FY, 2020) | Products N/A | Products 300 k (FY, 2021) | Products 21 (FY, 2021) | Products N/A | Products N/A | Products N/A |
Registration Phase Products | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products 8 (FY, 2022) | Registration Phase Products 10 (FY, 2021) | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products N/A |
Funding | ||||||||||||
Total funding raised | Total funding raised $ 1b | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 6.5m | Total funding raised N/A | Total funding raised $ 650m | Total funding raised N/A | Total funding raised $ 121m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 307.2m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Eli Lilly
HQ
Employees
35,000
Eli Lilly and Company is a company that discovers, develops, manufactures, and markets pharmaceutical products.
View companyJohnson & Johnson
HQ
New Brunswick, US
Employees
152,700
Johnson & Johnson (J&J) is a company that engages in the research and development, manufacture, and sale of a range of products in the healthcare field.
View companyNovartis
HQ
Basel, CH
Employees
101,703↓ 3% decrease
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
View companyPfizer
HQ
New York, US
Employees
83,000↑ 5% increase
Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.
View company